Investigational drug · Phase 3
Berobenatide
Also called: PF-08653944, MET097, MET-097i
Not approved by FDA. In 19 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Overweight and/or Obesity, Overweight.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
19
14 still active
All registered trials
12
Any phase or sponsor naming "Berobenatide"
First trial start
2024
Apr 1, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
- Pfizer18
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Berobenatide", any sponsor or status.
- Phase 311
Conditions studied
As listed on its trial records.
- Obesity
- Overweight and/or Obesity
- Overweight
- Overweight or Obesity
- Apnea
- Sleep Disorders
- Obesity and Overweight
- Overnutrition
- Nutrition Disorders
- Nutritional and Metabolic Diseases
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Berobenatide" as an intervention, largest first.
- A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or ObesityPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07595549 · 954 participants (planned) · Start Jun 10, 2026 · Primary completion May 4, 2028
Drug: PF-08653944 · For: Obesity; Overweight and/or Obesity; Overweight
Sites: Canoga Park, California; Escondido, California; Modesto, California · 80 sites in all
- A Study to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or Overweight (VESPER-SUI)Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07932925 · 900 participants (planned) · Start Nov 17, 2026 · Primary completion Oct 13, 2028
Drug: Berobenatide; Placebo · For: Urinary Incontinence, Stress; Overweight and/or Obesity
Sites: Citrus Heights, California; Sacramento, California; Boynton Beach, Florida · 11 sites in all
- A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07915609 · 756 participants (planned) · Start Oct 26, 2026 · Primary completion Aug 21, 2028
Drug: Berobenatide; Placebo · For: Obesity; Overweight and/or Obesity; Knee Osteoarthritis and 1 more
Sites: Birmingham, Alabama; Tucson, Arizona; Miami, Florida · 4 sites in all
- A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or ObesityPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07845500 · 660 participants (planned) · Start Sep 30, 2026 · Primary completion Feb 16, 2028
Drug: Semaglutide; Berobenatide and 1 more · For: Obesity; Overweight and/or Obesity; Overweight and 1 more
Sites: Birmingham, Alabama; Canoga Park, California; Los Angeles, California · 26 sites in all
- A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07919678 · 656 participants (planned) · Start Oct 26, 2026 · Primary completion Aug 22, 2028
Drug: Berobenatide · For: Obesity; Overweight; Osteoarthritis of the Knee
Sites: Tempe, Arizona; Escondido, California; Rancho Cucamonga, California · 40 sites in all
- A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or ObesityPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07874633 · 432 participants (planned) · Start Oct 28, 2026 · Primary completion Jun 6, 2028
Drug: Berobenatide · For: Obesity; Overweight
Sites: Hefei, China; Beijing, China; Huizhou, China · 6 sites in all
- A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or ObesityPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07792954 · 300 participants (planned) · Start Sep 24, 2026 · Primary completion Mar 14, 2028
Drug: Berobenatide · For: Obesity; Overweight
Sites: Hefei, China; Beijing, China; Chongqing, China · 34 sites in all
- A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07881757 · 258 participants (planned) · Start Oct 19, 2026 · Primary completion Jun 1, 2028
Drug: Berobenatide; Placebo · For: Apnea; Sleep Disorders; Overweight and/or Obesity
Sites: Cullman, Alabama; Bradenton, Florida; Maplewood, Minnesota · 4 sites in all
- A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07823608 · 258 participants (planned) · Start Sep 17, 2026 · Primary completion Apr 30, 2028
Drug: Berobenatide · For: Apnea; Sleep Disorders; Overweight and/or Obesity
Sites: Cullman, Alabama; Little Rock, Arkansas; Riverside, California · 8 sites in all
- A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07794774 · 197 participants (planned) · Start Sep 29, 2026 · Primary completion Feb 21, 2029
Drug: Berobenatide · For: Obesity
Sites: Mihama-ku, Japan; Matsuyama, Japan; Fukuoka, Japan · 36 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.